DRUG DEVELOPMENT PIPELINE Trademark

Trademark Overview


On Thursday, March 4, 1999, a trademark application was filed for DRUG DEVELOPMENT PIPELINE with the United States Patent and Trademark Office. The USPTO has given the DRUG DEVELOPMENT PIPELINE trademark a serial number of 75653579. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Wednesday, June 7, 2000. The DRUG DEVELOPMENT PIPELINE trademark is filed in the Paper & Printed Material Products category with the following description:

Newsletter

General Information


Serial Number75653579
Word MarkDRUG DEVELOPMENT PIPELINE
Filing DateThursday, March 4, 1999
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateWednesday, June 7, 2000
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesNewsletter

Classification Information


International Class016 - Paper, cardboard and goods made from these materials, not included in other classes; printed matter; bookbinding material; photographs; stationery; adhesives for stationery or household purposes; artists' materials; paint brushes; typewriters and office requisites (except furniture); instructional and teaching material (except apparatus); plastic materials for packaging (not included in other classes); printers' type; printing blocks.
US Class Codes002, 005, 022, 023, 029, 037, 038, 050
Class Status Code6 - Active
Class Status DateFriday, April 16, 1999
Primary Code016
First Use Anywhere DateWednesday, May 1, 1996
First Use In Commerce DateWednesday, May 1, 1996

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressMaplewood, NJ 07040

Trademark Events


Event DateEvent Description
Wednesday, June 7, 2000ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Monday, September 13, 1999NON-FINAL ACTION MAILED
Thursday, August 26, 1999ASSIGNED TO EXAMINER

Related Keywords


pipeline development drug newsletter